Company Information

    Casma Therapeutics was founded on January 2017. The company is based in Cambridge, MA, USA . The number of employees in Casma Therapeutics is less than 50. Casma therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Casma Therapeutics has received 3 rounds of venture funding. The total funding amount is around $108.9M. Last venture funding round was $50M, announced on September, 2020.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Casma Therapeutics - Blog

                          • Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology

                          • CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design new medicines, today announced the publication of new research findings in Science Advances co-authored by Casma scientists, along with Oliver Florey, Ph.D., of the Brabraham Institute, and Casma scientific co-founder Andrea Ballabio, M.D., of the Telethon Institute […]
                          • Casma Therapeutics Announces Addition of Sharon Tooze, Ph.D. to Scientific Advisory Board

                          • CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Sharon Tooze, Ph.D. to its scientific advisory board (SAB). “We are thrilled to welcome Sharon to our SAB at this pivotal stage of Casma’s growth,” stated Leon […]
                          • Casma Therapeutics to Present at Oppenheimer Rare & Orphan Disease Summit

                          • CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. […]
                          • Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement

                          • CAMBRIDGE, Mass. & COPENHAGEN, Denmark- December 1, 2020-Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets. Casma […]
                          • Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors

                          • CAMBRIDGE, Mass.-November 17, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Nagesh Mahanthappa, Ph.D., MBA, to its Board of Directors. “We are pleased to welcome Nagesh to our Board of Directors at this significant next stage of Casma’s development,” stated Keith […]
                          • Casma Therapeutics Announces $50 Million Series B Financing

                          • Funding led by The Column Group Proceeds will be used to advance Casma’s First-in-Class TRPML1 agonist in muscular dystrophy and enable preclinical proof-of-concept for the Company’s novel autophagy degrader platform CAMBRIDGE, Mass.-September 10, 2020 –Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of […]

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *